Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
The U.S. Meals and Drug Administration (FDA) has accepted PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to assist establish sufferers with epithelial...
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) introduced a big addition to its drug pipeline with the acquisition of CT-95 from Hyperlink...
SufferersOf the 802 sufferers with RAS WT mCRC included within the PARADIGM efficacy evaluation inhabitants, 733 sufferers (91.4%) supplied knowledgeable consent for this...
